Bellerophon Therapeutics, Inc. BLPH Cash Flow

Bellerophon therapeutics, inc. (BLPH)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14
Cash flows from operating activities:
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-59,674	0	0	0
Net Income (Loss) Attributable to Parent
-17,442	-13,267	-10,099	5,289	-2,077	2,814	-20,433	-39,120	-31,579	-54,818	-38,082	-34,691	-35,898	-23,814	-27,217	-34,164	-40,610	-46,459	0	0	0	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Fair Value Adjustment of Warrants
-172	-2,682	-6,180	-23,805	-19,443	-24,877	-4,253	15,022	8,966	30,403	14,045	12,610	14,977	590	0	0	0	-	-	-	-	-	-	-	-
Accretion and amortization of discounts and premiums on marketable securities, net
-	-	-	-	-	-	-	0	0	-	-	0	0	-	0	0	0	-	0	0	0	-	-	-	-
Stock based compensation
1,612	2,152	2,601	2,931	3,247	2,955	2,822	3,074	2,828	2,841	2,744	2,767	2,886	2,758	2,655	2,313	1,908	1,751	1,784	1,610	2,012	1,839	0	0	0
Depreciation
306	348	354	357	359	362	361	362	365	373	382	390	395	400	405	396	389	377	367	373	378	388	0	0	0
Changes in operating assets and liabilities:
Receivables due from Ikaria, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-
Prepaid expenses and other current assets
-599	-245	-1,026	-1,666	-2,068	-2,709	-2,196	-2,871	-3,426	-2,972	-2,431	-43	715	946	4,921	3,566	3,753	3,783	-127	413	470	50	0	0	0
Restricted cash held for Ikaria, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Increase (Decrease) in Restricted Cash for Operating Activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Other non-current assets
-	-	-	-	-	-54	-15	-436	-869	-1,437	-3,245	-5,133	-5,076	-5,210	3,304	5,595	5,985	6,701	0	0	0	-	-	-	-
Accounts payable, accrued research and development, and accrued expenses
0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable, accrued research and development, and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0
Amounts due to Ikaria, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-910	-	0	0	0	-	-	-	-
Increase in amounts due to Ikaria, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-45,194	-48,765	-70,562	0	0	0
Net cash used in operating activities
-14,932	-12,936	-14,102	-15,516	-17,391	-15,495	-15,932	-13,787	-12,683	-15,896	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities:
Capital expenditures
-	-	-	-	-	-	-	-	-	-	-	-	-	22	56	480	480	458	0	0	0	-	-	-	-
Purchase of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	0	3,892	18,592	22,757	22,757	0	0	0	-	-	-	-
Proceeds from sale of marketable securities
-	-	-	-	-	-	-	-	-	8,558	7,030	9,986	12,954	12,221	14,006	10,795	6,635	4,910	0	0	0	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	2,577	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities:
Proceeds from sale of Units in PIPE Offering, net of offering expenses
-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0	-	-	-	-
Proceeds received from exercise of warrants
3,100	0	0	0	0	-	-	-	-	2,299	747	520	520	0	0	0	0	-	-	-	-	-	-	-	-
Contribution from Ikaria, Inc. in connection with Spin-Out
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	80,000	0	0	0
Contributions from Ikaria, Inc., net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,252	0	0	0
Payment of offering expenses related to the secondary offering
-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock in Public Offering
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of membership units
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	0	0	0	-	-	-	-
Payment of offering expenses related to the PIPE offering
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of Units in Direct Offering, net of commissions and offering expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
Cash proceeds from issuance of common stock from initial public offering, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53,827	0	0	0	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	53,172	53,036	87,377	0	0	0
Net cash provided by (used in) financing activities
2,850	6,167	6,236	6,261	6,568	166	1,271	24,910	27,471	27,784	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash, cash equivalents and restricted cash
-12,082	-6,769	-6,867	-6,757	-7,823	-12,329	-12,476	12,532	14,907	14,465	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash financing activities:
Net change in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-19,978	-47,205	-61,665	-10,555	-6,697	3,813	4,271	16,815	0	0	0
Non-cash investing activities:
Unpaid expenses related to offerings
0	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in unrealized holding gains on marketable securities, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2	2	2	-19	0	0	0	-	-	-	-
Contribution of property, plant and equipment from Ikaria, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0
Non-cash financing activities:
Conversion of warrant liability to common stock upon exercise of warrants
-	-	-	-	-	-	-	-	-	4,411	1,005	702	702	0	0	0	0	-	-	-	-	-	-	-	-